Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications. | ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise ...